Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models

Alessia Romussi, Anna Cappa, Paola Vianello, Silvia Brambillasca, Maria Rosaria Cera, Roberto Dal Zuffo, Giovanni Fagà, Raimondo Fattori, Loris Moretti, Paolo Trifirò, Manuela Villa, Stefania Vultaggio, Valentina Cecatiello, Sebastiano Pasqualato, Giulio Dondio, Chi Wai Eric So, Saverio Minucci, Luca Sartori, Mario Varasi, Ciro Mercurio

Research output: Contribution to journalArticlepeer-review


Lysine-specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent enzyme that acts as a transcription corepressor or coactivator by regulating the methylation status of histone H3 lysines K4 and K9, respectively. KDM1A represents an attractive target for cancer therapy. While, in the past, the main medicinal chemistry strategy toward KDM1A inhibition was based on the optimization of ligands that irreversibly bind the FAD cofactor within the enzyme catalytic site, we and others have also identified reversible inhibitors. Herein we reported the discovery of 5-imidazolylthieno[3,2-b]pyrroles, a new series of KDM1A inhibitors endowed with picomolar inhibitory potency, active in cells and efficacious after oral administration in murine leukemia models.

Original languageEnglish
Pages (from-to)754-759
Number of pages6
JournalACS Medicinal Chemistry Letters
Issue number5
Publication statusPublished - May 14 2020


  • epigenetics
  • KDM1A
  • leukemia
  • LSD1
  • lysine-specific demethylase-1
  • Reversible inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models'. Together they form a unique fingerprint.

Cite this